

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format.

The following claims have been added:

- Claim 17 – basis for this claim is to be found at page 15, line 20 of the published PCT application.
- Claim 18 - basis for this claim is to be found at page 31, lines 5-24 of the published PCT application.
- Claim 19 - a claim directed towards the specific examples.
- Claims 20-22 - basis for these claims is to be found at page 49 line 25 - page 50 line 4 of the published PCT application.

No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101160-1P US.

Respectfully submitted,



Name: Lucy Padget
Dated: January 26, 2006
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451